Identification of protein kinase C activation as a novel mechanism for RGS2 protein upregulation through phenotypic screening of natural product extracts.
Avi Raveh, Pamela J Schultz, Lauren Aschermann, Colleen Carpenter, Giselle Tamayo-Castillo, Shugeng Cao, Jon Clardy, Richard R Neubig, David H Sherman, Benita Sjögren
Index: Mol. Pharmacol. 86(4) , 406-16, (2014)
Full Text: HTML
Abstract
Biochemical high-throughput screening is widely used in drug discovery, using a variety of small molecule libraries. However, broader screening strategies may be more beneficial to identify novel biologic mechanisms. In the current study we used a β-galactosidase complementation method to screen a selection of microbial-derived pre-fractionated natural product extracts for those that increase regulator of G protein signaling 2 (RGS2) protein levels. RGS2 is a member of a large family of proteins that all regulate signaling through G protein-coupled receptors (GPCRs) by accelerating GTPase activity on active Gα as well as through other mechanisms. RGS2(-/-) mice are hypertensive, show increased anxiety, and are prone to heart failure. RGS2 has a very short protein half-life due to rapid proteasomal degradation, and we propose that enhancement of RGS2 protein levels could be a beneficial therapeutic strategy. Bioassay-guided fractionation of one of the hit strains yielded a pure compound, Indolactam V, a known protein kinase C (PKC) activator, which selectively increased RGS2 protein levels in a time- and concentration-dependent manner. Similar results were obtained with phorbol 12-myristate 13-acetate as well as activation of the Gq-coupled muscarinic M3 receptor. The effect on RGS2 protein levels was blocked by the nonselective PKC inhibitor Gö6983 (3-[1-[3-(dimethylamino)propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione), the PKCβ-selective inhibitor Ruboxastaurin, as well as small interfering RNA-mediated knockdown of PKCβ. Indolactam V-mediated increases in RGS2 protein levels also had functional effects on GPCR signaling. This study provides important proof-of-concept for our screening strategy and could define a negative feedback mechanism in Gq/Phospholipase C signaling through RGS2 protein upregulation. Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.
Related Compounds
Related Articles:
2002-02-14
[J. Med. Chem. 45(4) , 853-60, (2002)]
2004-09-01
[Bioorg. Med. Chem. 12(17) , 4575-83, (2004)]
2004-01-01
[Curr. Pharm. Des. 10(12) , 1371-85, (2004)]
2002-07-01
[Biosci. Biotechnol. Biochem. 66(7) , 1615-7, (2002)]
2007-03-01
[J. Physiol. 579(Pt 2) , 363-73, (2007)]